Investment analysts at Oppenheimer started coverage on shares of Arcosa (NYSE:ACA – Get Free Report) in a research note issued to investors on Thursday. The brokerage set an “outperform” rating and a $150.00 price target on the stock. Oppenheimer’s price target points to a potential upside of 19.76% from the stock’s previous close.
ACA has been the topic of several other research reports. Wall Street Zen lowered shares of Arcosa from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. DA Davidson upped their target price on Arcosa from $120.00 to $125.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Barclays increased their price target on Arcosa from $115.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Weiss Ratings lowered Arcosa from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, May 11th. Finally, Zacks Research downgraded Arcosa from a “hold” rating to a “strong sell” rating in a research note on Tuesday, April 28th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $138.33.
Get Our Latest Research Report on Arcosa
Arcosa Stock Performance
Arcosa (NYSE:ACA – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.38. Arcosa had a net margin of 7.88% and a return on equity of 8.52%. The company had revenue of $571.70 million for the quarter, compared to the consensus estimate of $642.40 million. During the same period last year, the firm posted $0.49 EPS. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. As a group, sell-side analysts forecast that Arcosa will post 4.22 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Arcosa
Several hedge funds and other institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC raised its stake in Arcosa by 20.6% during the 1st quarter. AQR Capital Management LLC now owns 8,326 shares of the company’s stock valued at $642,000 after acquiring an additional 1,423 shares in the last quarter. United Services Automobile Association bought a new position in shares of Arcosa in the first quarter worth $256,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Arcosa by 11.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 143,244 shares of the company’s stock valued at $11,047,000 after purchasing an additional 14,723 shares during the period. Jane Street Group LLC increased its holdings in shares of Arcosa by 193.8% during the first quarter. Jane Street Group LLC now owns 105,243 shares of the company’s stock valued at $8,116,000 after purchasing an additional 69,427 shares during the period. Finally, American Century Companies Inc. raised its stake in shares of Arcosa by 1.4% during the second quarter. American Century Companies Inc. now owns 12,690 shares of the company’s stock valued at $1,100,000 after purchasing an additional 181 shares in the last quarter. 90.66% of the stock is currently owned by institutional investors and hedge funds.
Arcosa Company Profile
Arcosa, Inc (NYSE: ACA) is a Dallas‐based industrial company that was formed through the spin‐off of Trinity Industries’ construction products business in 2018. Since its inception, Arcosa has focused on the manufacture and sale of critical infrastructure components, serving a diverse set of end markets including transportation, construction and energy.
The company’s Construction Products segment produces a broad range of highway safety products, such as guardrail systems, sign supports and crash cushions, as well as aggregates and ready‐mix concrete.
Recommended Stories
- Five stocks we like better than Arcosa
- Semtech’s Explosive Rally May Only Be Getting Started
- Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?
- The Food Delivery War Just Entered Its Final Phase
- Bath & Body Works Stock Surged Despite Falling Sales—Here’s Why
Receive News & Ratings for Arcosa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcosa and related companies with MarketBeat.com's FREE daily email newsletter.
